The article discusses the key issues of the role of family medicine in our country and abroad in the changing medical paradigm and the transition to personalized preventive medicine. The leading role of the family doctor in building new scenarios of relations with patient communities based on trust, combining all types of material and spiritual resources, and moving to a model of conscious health management is justified.

The article summarizes the long-term experience of practical application of domestic breakthrough technologies of preventive personalized medicine for laboratory diagnostics of a wide range of socially significant non-infectious diseases. Conceptual approaches to the formation of an integrated program for early detection and prevention of civilization diseases based on these technologies are given. A vision of the prospects for the development of this area in domestic and foreign medicine has been formed.

Background: Chronic recurrent pain is a clinical symptom of rheumatologic diseases with primary joint damage. The mechanisms of chronic pain syndrome development are often associated with depression. Methods: The study enrolled 67 patients with ostheoarthrosis (OA), rheumatoid arthritis (RA) and lower back pain. The average subject age was 59, 5 ± 5, 3; 24 were males and 43 were females. In order to achieve the study objective, Luscher test, CES-D; TAS; Spielberg-Hanin's scale; MMPI; VAS scale and McGill Pain Questionnaire were used. Results: Following the testing results, 32 (47,8%) of 67 patients were diagnosed with chronic pain syndrome associated with depression respectively р=0,002. The average pain syndrome (PS) level by VAS scale in patients with depression was almost 1,7 times higher than in patients without psychological disorders, 8,6±0,9 vs. 5,2±1,09; р <0,001. Under adaptive tension conditions, when the MMPI profile exceeded 70 Т-scores, PS tended to exacerbate (р<0,001), while manifestation of depression symptoms correlated with PS (г= 0,627) and the presence of personality traits accentuation (г= 0,531), along with increased anxiety (г= 0,425), asthenic condition (г= 0,392) and general TAS alexithymia score (г= 0,473). After the course of therapy involving antidepressant drugs, PS decreased by 2,9 times as compared to the baseline level, р <0,001. Conclusion: Indications for antidepressant use in patients with PS include the chronic pain syndrome associated with depression at the background of basic anti-inflammatory therapy.

Background: Phenomenon of psychological mechanisms specific gravity/significance determination in the pathologic behavior of functional intestinal disorders of various forms has claimed attention from physicians and psychologists for the more than 40 years. Methods: The study enrolled 114 patients (26 male and 88 female) with irritable bowel syndrome (IBS-D, IBS-C, IBS-M and IBS-U), functional constipation (FC) and functional diarrhea (FD). The average subject age was 43,6±11 years. In order to achieve the study objective, MMPI method was used, where the range between 30 and 70 T-scores indicated normal psychological condition, while increased score by one or several clinical scales were deemed to signal the pathological profile. Results: Analysis of averaged subject profiles showed that in most subjects the average profile score exceeded 80 Т-scores, and namely in 64% FC patients, 60% IBS-M patients and 56% IBS-C patients vs. 44% IBS-U patients, 43% IBS-D patients and 33% FD patients, р˂ 0,01. The average profile above 70 Т-scores, but below 80 Т-scores by one or several clinical scales was observed in 50% for FD vs. 32% for IBS-D; р<0,01; and twice as often for IBS-C: 33% vs. 16% for FC. In the lower part of continuum, where the psychological factor influence is relatively low, the profile distribution was as follows: 25% for IBS-D, 20% for FC and IBS-M, 17% for FD and IBS-M, 11% for IBS-C. Conclusion:The data obtained demonstrate the significant specific gravity of psychosomatic component in disease development, progression and chronization in patients with FC, IBS-M.